Trinity Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Trinity Biotech plc
TRIB Stock  USD 0.75  0.04  5.06%   
Trinity Biotech's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Trinity Biotech's valuation are provided below:
Gross Profit
21.4 M
Profit Margin
(0.52)
Market Capitalization
15.9 M
Enterprise Value Revenue
2.5451
Revenue
61.6 M
We have found one hundred twenty available fundamental trend indicators for Trinity Biotech plc, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Trinity Biotech plc current market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. As of January 3, 2026, Market Cap is expected to decline to about 89.9 M. In addition to that, Enterprise Value is expected to decline to about 159.5 M

Trinity Biotech Total Revenue

78.33 Million

Check Trinity Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Trinity Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.5 M, Total Revenue of 78.3 M or Gross Profit of 35 M, as well as many indicators such as Price To Sales Ratio of 1.4, Dividend Yield of 0.0019 or Days Sales Outstanding of 90.37. Trinity financial statements analysis is a perfect complement when working with Trinity Biotech Valuation or Volatility modules.
  
Build AI portfolio with Trinity Stock
Check out the analysis of Trinity Biotech Correlation against competitors.

Trinity Biotech Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets142.5 M118.8 M158.4 M
Slightly volatile
Short and Long Term Debt Total121.7 M115.9 M85.3 M
Slightly volatile
Total Current Liabilities23.4 M36.9 M25.2 M
Slightly volatile
Property Plant And Equipment Net10.3 M5.3 M8.5 M
Slightly volatile
Accounts Payable10.1 M7.9 M11.7 M
Pretty Stable
Cash5.6 M5.9 M31.9 M
Slightly volatile
Non Current Assets Total72.7 M71.5 M79.5 M
Slightly volatile
Cash And Short Term Investments5.6 M5.9 M31.9 M
Slightly volatile
Net Receivables17.2 M16.8 M19 M
Very volatile
Common Stock Shares Outstanding21.7 M20.7 M11 M
Pretty Stable
Liabilities And Stockholders Equity142.5 M118.8 M158.4 M
Slightly volatile
Non Current Liabilities Total128.4 M122.3 M72.8 M
Slightly volatile
Inventory26 M22.3 M25.7 M
Pretty Stable
Total Liabilities167.2 M159.2 M98.9 M
Slightly volatile
Total Current Assets69.8 M47.3 M78.9 M
Slightly volatile
Short Term Debt2.7 M2.9 M8.1 M
Pretty Stable
Intangible Assets42.2 M43.1 M43.1 M
Pretty Stable
Common Stock Total Equity994.6 K1.4 M1.2 M
Slightly volatile
Property Plant And Equipment Gross85.3 M81.2 M31.6 M
Slightly volatile
Common Stock5.1 M4.8 M1.9 M
Slightly volatile
Long Term Debt106 M101 M58.9 M
Slightly volatile
Property Plant Equipment9.6 M5.3 M9.1 M
Slightly volatile
Other Liabilities6.2 M5.6 M8.2 M
Very volatile
Current Deferred Revenue168.4 K177.3 K776.2 K
Slightly volatile
Other Assets4.7 M5 M20.4 M
Pretty Stable
Deferred Long Term Liabilities15.1 M15.9 M36 M
Slightly volatile
Short and Long Term Debt179.6 K189 K22 M
Very volatile
Long Term Debt Total74.5 M89.8 M95 M
Slightly volatile
Capital Surpluse12.9 M14.6 M15.9 M
Slightly volatile
Capital Lease Obligations11.8 M14.7 M7.6 M
Slightly volatile
Non Current Liabilities Other1.1 M2.1 M1.3 M
Slightly volatile
Net Invested Capital67.5 M47.5 M111.6 M
Slightly volatile
Capital Stock5.1 M4.8 M1.9 M
Slightly volatile

Trinity Biotech Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization3.5 M2.1 M3.3 M
Pretty Stable
Total Revenue78.3 M70.8 M79.9 M
Very volatile
Gross Profit35 M24.7 M35 M
Pretty Stable
Other Operating Expenses78.3 M95.1 M79 M
Slightly volatile
Cost Of Revenue44 M46.1 M46.1 M
Slightly volatile
Total Operating Expenses34.7 M49 M33.5 M
Slightly volatile
Interest Expense11.5 M11 M6.3 M
Slightly volatile
Selling General Administrative24.1 M33.1 M26.1 M
Slightly volatile
Research Development5 M5.2 M4.4 M
Slightly volatile
Selling And Marketing Expenses23.6 M29 M30.4 M
Very volatile
Non Recurring37.2 M37.6 M43.9 M
Slightly volatile
Reconciled Depreciation2.6 M1.7 M3.9 M
Slightly volatile

Trinity Biotech Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow4 M4.2 M34.9 M
Slightly volatile
Depreciation3.5 M2.1 M3.4 M
Pretty Stable
Capital Expenditures10 M11.6 M12.9 M
Slightly volatile
End Period Cash Flow5.6 M5.9 M32 M
Slightly volatile
Stock Based Compensation1.4 M1.5 M1.4 M
Very volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.41.4820.5488
Slightly volatile
Dividend Yield0.00190.00340.0031
Slightly volatile
Days Sales Outstanding90.3799.5983.2071
Slightly volatile
Average Payables3.3 M3.8 M3.3 M
Slightly volatile
Stock Based Compensation To Revenue0.01260.01920.0166
Slightly volatile
Capex To Depreciation3.826.213.7132
Very volatile
EV To Sales3.13.2621.0315
Slightly volatile
Inventory Turnover3.322.382.1542
Very volatile
Days Of Inventory On Hand164159191
Very volatile
Payables Turnover8.296.757.0838
Slightly volatile
Sales General And Administrative To Revenue0.220.270.2685
Slightly volatile
Average Inventory14.2 M22.9 M23.9 M
Very volatile
Research And Ddevelopement To Revenue0.07210.08490.06
Slightly volatile
Capex To Revenue0.140.190.1677
Slightly volatile
Cash Per Share0.250.267.0695
Slightly volatile
Payout Ratio0.20.210.231
Very volatile
Days Payables Outstanding66.9771.560.0904
Slightly volatile
Intangibles To Total Assets0.30.450.3783
Pretty Stable
Current Ratio1.11.153.7999
Slightly volatile
Receivables Turnover5.824.854.618
Very volatile
Capex Per Share0.480.52.6121
Slightly volatile
Average Receivables13.8 M15.9 M16.8 M
Pretty Stable
Revenue Per Share2.933.0815.536
Slightly volatile
Interest Debt Per Share6.895.5312.0072
Slightly volatile
Debt To Assets0.920.880.5592
Slightly volatile
Graham Number0.50.521.2336
Slightly volatile
Operating Cycle230237271
Very volatile
Days Of Payables Outstanding66.9771.560.0904
Slightly volatile
Dividend Payout Ratio0.20.210.231
Very volatile
Long Term Debt To Capitalization1.581.50.7796
Slightly volatile
Total Debt To Capitalization1.451.380.7627
Slightly volatile
Quick Ratio0.580.612.6358
Slightly volatile
Cash Ratio0.140.1611.6727
Slightly volatile
Days Of Inventory Outstanding164159191
Very volatile
Days Of Sales Outstanding90.3799.5983.2071
Slightly volatile
Fixed Asset Turnover7.0611.9911.2388
Slightly volatile
Debt Ratio0.920.880.5592
Slightly volatile
Price Sales Ratio1.41.4820.5488
Slightly volatile
Asset Turnover0.70.690.5769
Slightly volatile
Gross Profit Margin0.330.310.4018
Pretty Stable

Trinity Biotech Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap89.9 M94.6 M750.3 M
Slightly volatile
Enterprise Value159.5 M167.9 M789.2 M
Slightly volatile

Trinity Fundamental Market Drivers

Trinity Upcoming Events

28th of March 2024
Upcoming Quarterly Report
View
4th of July 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Trinity Biotech Financial Statements

Trinity Biotech stakeholders use historical fundamental indicators, such as Trinity Biotech's revenue or net income, to determine how well the company is positioned to perform in the future. Although Trinity Biotech investors may analyze each financial statement separately, they are all interrelated. For example, changes in Trinity Biotech's assets and liabilities are reflected in the revenues and expenses on Trinity Biotech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Trinity Biotech plc. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue177.3 K168.4 K
Total Revenue70.8 M78.3 M
Cost Of Revenue46.1 M44 M
Stock Based Compensation To Revenue 0.02  0.01 
Sales General And Administrative To Revenue 0.27  0.22 
Research And Ddevelopement To Revenue 0.08  0.07 
Capex To Revenue 0.19  0.14 
Revenue Per Share 3.08  2.93 
Ebit Per Revenue(0.31)(0.29)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
JBLJabil Circuit
MRKMerck Company
AMGNAmgen Inc
When determining whether Trinity Biotech plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trinity Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trinity Biotech Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trinity Biotech Plc Stock:
How To Invest In Trinity
Details
Is Trinity Stock a good investment?
Details
What is Trinity Biotech's Net Worth?
Details
Largest Health Care Equipment & Supplies Companies
View
Largest Health Care Equipment & Services Companies
View
Check out the analysis of Trinity Biotech Correlation against competitors.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Biotech. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trinity Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.77)
Earnings Share
(1.80)
Revenue Per Share
3.427
Quarterly Revenue Growth
0.181
Return On Assets
(0.11)
The market value of Trinity Biotech plc is measured differently than its book value, which is the value of Trinity that is recorded on the company's balance sheet. Investors also form their own opinion of Trinity Biotech's value that differs from its market value or its book value, called intrinsic value, which is Trinity Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trinity Biotech's market value can be influenced by many factors that don't directly affect Trinity Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Trinity Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Trinity Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY